Live date: Tuesday 25 February 2020 15:00 [GMT] 10:00 [EST] 07:00 [PST]. This webinar will provide an overview of the current applications of flow cytometry in the drug development process and the future outlook of the flow cytometry field in a regulated environment.
Live date: Thursday 27 February 2020 15:00 [GMT] 10:00 [EST] 07:00 [PST]. Bioanalysis Zone is delighted to offer its members unique access to this panel discussion focusing on new technologies. The panelists discuss how the bioanalytical field could learn from other industries and why we should be introducing new technologies.
Available on demand. Register for our exclusive Coffee Chat focusing on developments in cell and gene therapies. This informal discussion centers around gene therapy medicinal products and their potential to change the way we fight disease.
Available on demand. LC–MS based large molecule bioanalysis platform was developed, validated and applied for drug screening and preclinical pharmacokinetics.
Available on demand. The demonstration of similar immunogenicity is a critical requirement for the demonstration of similarity between a biosimilar candidate and the respective reference product.
Webinar now available on demand. The aim of DMPK is to enable scientists to learn the safety and efficacy of new molecular entities. HRMS is an important analytical tool used to study DMPK that continues to gain traction when quantifying molecules.
Webinar now available on demand. Absolute quantitation of intact biotherapeutics is enabled through advances in immunocapture techniques coupled to LC–MS.
Webinar live date: Thursday 12 December 2019 07:00 [PST] 10:00 [EST] 15:00 [GMT]. On December 12, join us as we discuss, with supporting case studies, how hybridization ELISA can be an effective approach to quantify antisense oligonucleotides in circulation and in their targeted tissue.
Panel discussion available on demand. In this free panel discussion, our experts will provide insights into their own research using oligonucleotides, including the most common challenges encountered, key trends they have seen as the field develops and their opinions on the future outlook of the technology.
Webinar now available on demand. Learn about the sensitivity gains afforded by microflow chromatography vs high-flow and what potential this has for Met ID. See how this translates to stronger spectra in turn resulting in more metabolites being identified and characterized.
Thank you everyone who attended our live webinar ‘Exploratory biomarker testing: to qualify or validate the assay? The latest scientific and regulatory considerations for biomarker validation‘ in association with BioAgilytix.
Thermo Fisher Scientific (MD, USA) have entered a collaboration with diagnostic platform designer, NanoPin Technologies (AZ, USA), to develop new LC–MS-based workflows to advance the detection technology available for blood-based infectious diseases.
Researchers have identified a metabolic biomarker that could be used to track the progression of arrhythmogenic cardiomyopathy – a genetic heart muscle disease that can cause life-threatening ventricular arrhythmias.
Molecular diagnostics company, Mobidiag (Espoo, Finland), has announced that it has initiated the development of a diagnostic assay for the simultaneous detection of novel coronavirus (2019-nCoV) and influenza viruses.
As part of our feature examining lab-on-a-chip technology, we interviewed lab-on-a-chip expert, Aaron Wheeler from the University of Toronto (Canada). Aaron described his experience and research in the field and explained to us that the age of lab-on-a-chip is upon us.
In this interview Zhiyu discusses where her inspiration came from and what motivated her to get involved with analytical chemistry. She details her journey of choosing mass spectrometry as a speciality and building the first LC–MS based large molecule bioanalysis platform in China.
In this presentation, Steve Kleiboeker (Viracor Eurofins; MO, USA) discusses CMV diagnostic testing; in particular the CMV T-cell immunity panel, which can help physicians predict which patients are at risk and be prepared to work with the patients pre-emptively before they develop the disease.